There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > BAFF


BAFF Molecule Information

Name:B-cell-activating factor/B lymphocyte stimulator
Target Synonym:TALL-1;BAFF;B-cell-activating factor;Tumor necrosis factor ligand superfamily member 13B;Tumor necrosis factor ligand superfamily member 13b, membrane form;TNFSF13B;TNF- and APOL-related leukocyte expressed ligand 1;BLyS;BLYS;TALL1;TNFSF20;BAFF ;Tumor nec
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

BAFF Protein Product ListCompare or Buy

BAFF Part of Bioactivity data

BAF-H52D4-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human BAFF, His,Flag Tag, active trimer (Cat. No. BAF-H52D4) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 1.97-2.90 ng/mL (Routinely tested).

BAF-H5261-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 4.91-9.81 ng/mL (Routinely tested).


Human BAFFR Protein, Fc Tag (Cat. No. BAR-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFF Protein, His,Flag Tag (Cat. No. BAF-H52D4) with an affinity constant of 5.54 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Immobilized Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) on CM5 Chip can bind Human TACI/TNFRSF13B, Fc Tag (Cat. No. TAI-H5256) with an affinity constant of 0.658 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BAFF Molecule Synonym Name


BAFF Molecule Background

B-cell activating factor (BAFF) is also known as tumor necrosis factor ligand superfamily member 13B , TNFSF13B, BAFF, B Lymphocyte Stimulator (BLyS) , cluster of differentiation 257 (CD257), DTL, TNF- and APOL-related leukocyte expressed ligand (TALL-1), THANK, TNFSF20, ZTNF4, and is a  cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. It is expressed as transmembrane protein on various cell types including monocytes, dendritic cells and bone marrow stromal cells. BAFF is the natural ligand of three unusual tumor necrosis factor receptors named BAFF-R, TACI, and BCMA, all of which have differing binding affinities for it. These receptors are expressed mainly on mature B lymphocytes (TACI is also found on a subset of T-cells and BCMA on plasma cells). TACI binds worst since its affinity is higher for a protein similar to BAFF, called a proliferation-inducing ligand (APRIL). BCMA displays an intermediate binding phenotype and will work with either BAFF or APRIL to varying degrees. Signaling through BAFF-R and BCMA stimulates B lymphocytes to undergo proliferation and to counter apoptosis. All these ligands act as heterotrimers (i.e. three of the same molecule) interacting with heterotrimeric receptors, although BAFF has been known to be active as either a hetero- or homotrimer. BAFF acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. 

BAFF References

BAFF Related Molecule

BAFF Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belimumab HGS-1006; GSK-1550188; BmAb,HGS1006; GSK1550188 Approved GlaxoSmithKline BENLYSTA fda Systemic lupus erythematosus HUMAN GENOME SCIENCES INC. 2011-03-09 Systemic lupus erythematosus Details

BAFF Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tibulizumab (Eli Lilly) Phase Ⅰ Lilly Sjoegren's syndrome Details
hCBE-11 hCBE-11,hCBE11,hCBE 11 Phase Ⅰ Biogen Solid tumours Details
MEDI-0700 MEDI-0700 Phase Ⅰ MedImmune Systemic lupus erythematosus Details
Mitumprotimut T Phase Ⅲ MMRGlobal Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) Details
UBP-1213 UBP-1213 Phase Ⅰ Wuhan Huaxin Kangyuan Biomedicine (Hubei), Shanghai Junshi Biosciences Systemic lupus erythematosus Details
Blisibimod A-623; AMG-623,A623,AMG623 Phase Ⅲ Anthera, Zenyaku Kogyo Systemic lupus erythematosus Details
Tabalumab LY-2127399 Phase Ⅲ Lilly Renal failure, Systemic lupus erythematosus, Multiple myeloma (MM), Multiple sclerosis (MS), Rheumatoid arthritis (RA) Details
Telitacicept RCT-18; RC-18,RCT18; RC18 BLA Filing Remegen Myasthenia gravis, Sjoegren's syndrome, Systemic lupus erythematosus, Multiple sclerosis (MS), Rheumatoid arthritis (RA), IgA nephropathy, Neuromyelitis optica (NMO) Details
Atacicept TACI-Ig Phase Ⅲ ZymoGenetics, Merck Serono Chronic lymphocytic leukemia (CLL), Lupus nephritis, Multiple myeloma (MM), Systemic lupus erythematosus, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Non-Hodgkin's lymphoma (NHL) Details
AMG-570 AMG-570  Phase Ⅱ Amgen, AstraZeneca Systemic lupus erythematosus Details
BAFF/IL-17 bispecific antibody Phase Ⅰ Lilly Immunological disorders Details

This web search service is supported by Google Inc.